¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lupus erythematosus test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® Mantoux test ÇÑ±Û ¸ÁÅä¿ì°Ë»ç
¼³¸í   
  ¼Ò¾Æ¿¡ ÁַΠ½Ç½ÃÇϴ °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª È¤Àº °áÇÙ±Õ¿¡ ÇѹøÀ̶󵵠³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼­´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼­ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀǠħÅõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù.
¿µ¹® stress test ÇÑ±Û ½ºÆ®·¹½º °Ë»ç
¼³¸í   
  Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î È¯ÀÚ¿¡°Ô¼­ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼­ È¯ÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼­ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù.
  
  ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼­µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³­´Ù.
¿µ¹® visual field test ÇÑ±Û ½Ã¾ß°Ë»ç
¼³¸í   
  ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ Ã¤, °üÂûÇÒ ¼ö Àִ ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇϴ °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃ߾¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤Çϴ °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼­ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, À̿ܠ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ.
¿µ¹® Draw a person test ÇÑ±Û Àι°È­ ¼º°Ý°Ë»ç
¼³¸í   
  Àι°È­ ¼º°Ý°Ë»ç´Â Ã³À½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ Àִ ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀڴ ±×¸®´Â ¼ø¼­¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼­ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇѴٴ ÀÔÀå, ±×¸²¿¡¼­ °­Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ­, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼭µµ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È­¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù.
¿µ¹® intelligence test ÇÑ±Û Áö´É°Ë»ç
¼³¸í   
  1905³â ÇÁ¶û½ºÀÇ ºñ³×°¡ Á¤½Å¹Ú¾à¾Æ¸¦ ÀϹݾƵ¿À¸·ÎºÎÅÍ ÆÇº°Çϱâ À§ÇÏ¿© ÀÛ¼ºÇÑ °ÍÀÌ Áö´É°Ë»çÀÇ ½ÃÀÛÀÌ´Ù. Áö´É°Ë»ç´Â ±×ÀÇ ¸ñÀûÀ¸·ÎºÎÅÍ ÀϹÝÀû Áö´É°Ë»ç¿Í Áø´Ü¿ë Áö´É°Ë»ç·Î ³ª´²Áö°í, ½Ç½Ã¹æ¹ý¿¡¼­ °³Àοë(°³º°½Ä)°ú Áý´Ü¿ë(´Üü½Ä)À¸·Î ºÐ·ùµÇ°í ¶Ç ¹®Á¦ÀÇ ³»¿ëÀ¸·ÎºÎÅÍ ¾ð¾î¼º°Ë»ç(A½Ä ¶Ç´Â ¥á½Ä)¿Í ºñ¾ð¾î¼º°Ë»ç(B½Ä ¥â½Ä)·Î ³ª´²Áø´Ù. Áö´É°Ë»çÀÇ °á°úÀǠǥ½Ã¹ýÀº Á¤½Å¿¬·É(mental age, MA), Áö´ÉÁö¼ö(intelligence quotient, IQ), Áö´ÉÆíÂ÷Ä¡(intelligence standard score, ISS)µîÀÌ ÀÖ´Ù. Áö´É°Ë»ç¿¡´Â ¿ª»çÀûÀ¸·Î ºñ³×½Ä°ú À°±º½ÄÀÇ µÎ °èÅëÀÌ ÀÖ´Ù. ºñ³×½ÄÀº °Ë»çÀÚ°¡ °³º°ÀûÀ¸·Î ÇÑ °³ ¹®Ç×¾¿ Áú¹®À» Çϸé ÀÌ¿¡ ´ëÇÏ¿© Çǰ˻çÀÚ°¡ ¸»À̳ª ÇൿÀ¸·Î ÀÀ´äÇϴ ¹æ¹ý(°³º°½Ä-¹®´ä½Ä)À̰í, À°±º½ÄÀº ÀϹÝÀûÀΠ¹æ½ÄÀ¸·Î´Â ÀμâµÈ ¹®Á¦¿ëÁö¸¦ »ç¿ëÇÏ¿© Çǰ˻çÀÚ°¡ ¼ÒÁ¤ÀÇ ½Ã°£ ³»¿¡ µÇµµ·Ï ¸¹ÀÌ ¹Ù¸£°Ô(½Ã°£Á¦Çѹý) È¸´äÀ» ±âÀÔÇÑ´Ù(Çʱâ¹ý). Çѱ¹ ÃÖÃÊÀÇ Áö´É°Ë»ç´Â 1954³â ¼­¿ï´ëÇб³ »ç¹ü´ëÇР±³À°½É¸®¿¬±¸½Ç¿¡¼­ Á¦ÀÛÇÑ °£Æí Áö´É°Ë»çÀÌ´Ù. °£Æí Áö´É°Ë»ç ÀÌÈÄ ´Ù¼öÀÇ Áý´Ü Áö´É°Ë»ç°¡ ÃâÇöÇÏ¿´´Âµ¥ ºñ±³Àû ÃÖ±Ù¿¡ Ç¥ÁØÈ­µÈ Áö´É°Ë»ç·Î´Â Çѱ¹Çൿ°úÇבּ¸¼Ò°¡ 1984³â¿¡ Àü±¹ °íµîÇб³ ÇлýÀ» ´ë»óÀ¸·Î Á¦ÀÛÇÑ KIT-S Áö´É°Ë»ç°¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus tumidus
    ºñ´ë·çǪ½º, ºÎÀº·çǪ½º
  • lupus vulgaris
    º¸Åë·çǪ½º
  • acceptance test
    Àμö°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • aptitude test
    Àû¼º°Ë»ç
  • articulation test
    ¹ßÀ½°Ë»ç
  • association test
    ¿¬»ó°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bronchial provocation test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs' test
    (¢¡antiglobulin test) ÄñÁî°Ë»ç
  • creatinine clearance test
    Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²°Ë»ç
  • D-xylose test
    Å©½Ç·Î¿À½º°Ë»ç
  • dip-stick test
    ¿ä½ÃÇèÁö°Ë»ç
  • estrogen challenge test
    ¿©¼ºÈ£¸£¸óºÎÇϰ˻ç
  • flashlight swinging test
    ±³´ëºÒºû°Ë»ç
  • glucose tolerance test
    ´çºÎÇϰ˻ç
  • guaiac test
    ÀáÇ÷°Ë»ç
  • Ham's test
    Çܰ˻ç
  • hemagglutination test
    Ç÷±¸ÀÀÁý½ÃÇè, Ç÷±¸ÀÀÁý°Ë»ç
  • HPV test
    (¢¡human papilloma virus test) »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
  • human papilloma virus test
    »ç¶÷À¯µÎÁ¾¹ÙÀÌ·¯½º°Ë»ç
  • inhibition test
    ¾ïÁ¦°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus vulgaris
    º¸Åë·çǪ½º
  • abrasion test
    ¸¶¸ê½ÃÇè
  • absorption test
    Èí¼ö½ÃÇè, Èí¼ö°Ë»ç
  • acceptance test
    Àμö°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
  • afterimage test
    ÀÜ»ó°Ë»ç
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • agglutination test
    ÀÀÁý°Ë»ç
  • air conduction test
    ±âµµ°Ë»ç, °ø±âÀüµµ°Ë»ç
  • alkali denaturation test
    ¾ËÄ®¸®º¯¼º°Ë»ç
  • alternate cover test
    ±³´ë°¡¸²°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ACTH stimulation test
    ACTH Àڱذ˻ç
  • Ames test
    ¿¡ÀÓ½º½ÃÇè
  • Ascolis test
    ¾Æ½ºÄݸ®½ÃÇè
  • Bacitracin differential disk test
    ¹Ù½ÃÆ®¶ó½Å°¨º°(¿ø)ÆÇ(÷ù)½ÃÇè
  • Bender-Gestalt test
    º¥´õ-°Ô½´Å»Æ® °Ë»ç
  • Benedict test
    º£³×µñÆ®½ÃÇè
  • Bentonite flocculation test
    º¥Å䳪ÀÌÆ® ¸é»óħÀü¹ý
  • Blondheim test
    ºí·ÐµåÇÏÀÓ½ÃÇè
  • Bonsignore test
    º»½Ã±×³ë½ÃÇè
  • C-Stix test
    C-½ºÆ½½º½ÃÇè<<¾Æ½ºÄÚ¸£ºó»ê½ÃÇè>>
  • CPT=£¾cold pressure test
    ³Ã¾Ð¹Ú½ÃÇè.
  • Callaways test
    Ķ·¯¿þÀ̽ÃÇè.
  • Carr-Price test
    Ä«¾Æ-ÇÁ¶óÀ̽º½ÃÇè.
  • Cartwright test
    īƮ¶óÀÌÆ®½ÃÇè
  • Casamajors test
    Ä«»ç¸ÞÁ¶¸£½ÃÇè.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus =LE ³ª
    È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus =le ³ª
    È«¹Ý¼º ·çǪ½º(ûõÚèàõ ¡­)
  • lupus erythematosus cell
    È«¹Ý¼º³¶Ã¢¼¼Æ÷
  • lupus erythematosus cell = LE cell
    È«¹Ý¼º ·çǪ½º¼¼Æ÷(¡­á¬øà)
  • lupus erythematosus disseminatus ³ª
    ÆÄÁ¾»ó(÷ëðúßÒ)È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • lupus erythematosus factor =LE f.
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­).
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾çÁõÈıº(ûõÚèàõ¡­åÆñøý¦ÏØ )
  • lupus erythematosus phenomenon = LE phenomenon
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ)
  • lupus erythematosus phenomenon =LE p.
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ).
  • lupus erythematosus profundus
    ½ÉÀ缺 È«¹Ý¼º ·çǪ½º
  • neonatal systemic lupus erythematosus
    ½Å»ý¾Æ Àü½Å¼º È«¹Ý¼º ·çǪ½º
  • sle= systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ·çǪ½º(îïãóàõ ûõÚèàõ¡­)
  • subacute cutaneous lupus erythematosus
    ¾Æ±Þ¼º ÇǺΠȫ¹Ý¼º ·çǪ½º
  • systemic lupus erythematosus
    Àü½Å¼ºÈ«¹Ý¼º·çÇÁ½º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • carbon clearance test
    ź¼Ò ûÁ¤½ÃÇè(÷©áÈôèïäãËúÐ)
  • cephalin-cholesterol flocculation test
    ¼¼ÆÈ¸°-ÄÝ·¹½ºÅ×·Ñ ¸é»ó½ÃÇè(ØúßÒãËúÐ)
  • chronic toxicity test
    ¸¸¼º µ¶¼º½ÃÇè(Ø·àõÔ¸àõãËúÐ)
  • cis-trans test
    ½Ã½ºÆ®¶õ½º ½ÃÇè(ãËúÐ)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
  • complementation test
    »óº¸½ÃÇè(ßÓÜÍãËúÐ)
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • complement fixation test
    º¸Ã¼°íÁ¤½ÃÇè(ÜÍô÷ͳïÒãËúÐ)
  • consumption test
    ¼Ò¸ð½ÃÇè(á¼ÙÄãËúÐ)
  • Coombs' test
    ÄñÁî ½ÃÇè(ãËúÐ)
  • cross-agglutination test
    ±³Â÷ÀÀÁý °Ë»ç(Îßó©ëêó¢ËþÞÛ)
  • Farr test
    ÆÄ¾Æ ½ÃÇè (ãËúÐ)
  • Fehling's test
    Æç¸µ ½ÃÇè(ãËúÐ)
  • fluctuation test
    ¿äµ¿ ½ÃÇè(èôÔÑãËúÐ)
  • Fouchet's test
    Ǫ½¦ °Ë»ç(ËþÞÛ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pivot shift test
    ÃßÃà º¯À§½ÃÇè
  • provocation test
    À¯¹ß½ÃÇè
  • provocative test
    À¯¹ß½ÃÇè
  • pulmonary function test
    Æó±â´É°Ë»ç
  • qualitative test
    Á¤¼º½ÃÇè
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • routine test
    »ó¿ë Å×½ºÆ®
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • serologic test
    Ç÷û(ÇÐÀû)°Ë»ç
  • sigle blind test
    ´ÜÀϸͽÃÇè
  • skin test
    ÇǺÎ(¹ÝÀÀ)°Ë»ç
  • supression test
    ¾ïÁ¦°Ë»ç
  • test
    ½ÃÇè, °Ë»ç(¹ý)
  • test object
    ½ÃÇè´ë»ó, Ç¥½Ä¹°
  • test phantom
    Ç¥ÁØÆÒÅÒ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CDLE chronic discoid lupus erythematosus
DIL, Dil Dilantin; drug-induced lupus [erythematosus]
DILE drug-induced lupus erythematosus
LE lactate extraction; left ear; left eye; leukocyte elastase; leukoerythrogenic; live embryo; Long Eva...
LED light-emitting diode; lowest emitting dose; lupus erythematosus disseminatus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
LBT Lupus band test
BILAG British Isles Lupus Assessment Group
DPLN Diffuse proliferative lupus nephritis
LAC Lupus AntiCoagulant
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lupus nephritis
    ³¶Ã¢¼º ½ÅÀå¿°
  • lupus vulagris
    ½É»ó¼º ³¶Ã¢, ½É»ó¼º ·çǪ½º, º¸Åë ·çǪ½º
    ÇǺÎÀÇ ¿ø¹ß¼º °áÇÙÀ¸·Î ±«¾ç¼ºÀÇ ±¸Áø¼º ¼Ò°áÀýÀ» º¸ÀÌ¸ç Æ¯È÷ ¾ó±¼¿¡ Àß ¹ß»ýÇÑ´Ù.
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • abrasion test
    ¸¶¸ê ½ÃÇè
    ¸¶¸ð¿¡ °ßµð´Â Á¤µµ¸¦ ½ÃÇèÇÏ´Â °Ë»ç.
  • acetest tablet test
    ¾Æ¼¼Å×½ºÆ® Á¤ ½ÃÇè
    ¹éÁö À§¿¡ ¿Ã·Á³õÀº ¾Æ¼¼Å×½ºÆ® Á¤¿¡ ¿ä ÇÑ ¹æ¿ïÀ» ¶³¾î¶ß¸± ¶§, ¾î´À Á¤µµÀÇ ¾Æ¼¼ÅæÀÌ Á¸ÀçÇÏ¸é ±× ¾ç¿¡ µû¶ó¼­ ¾Æ¼¼Å×½ºÆ® Á¤ÀÌ ´ãÀÚ»ö
  • acetoacetic acid test
    ¾Æ¼¼Åä ÃÊ»ê ½ÃÇè
  • achievement test
    ¼öµæ´É·Â °Ë»ç, ¼öµæ´É·Âµµ °Ë»ç
  • acid elution test
    »ê ¿ë¸® ½ÃÇè
    ÅÂ¾Æ Çì¸ð±Û·ÎºóÀÇ °ËÃâ ½ÃÇèÀ¸·Î, ½½¶óÀÌµå ±Û¶ó½º À§¿¡ °ø±â °ÇÁ¶µÈ Ç÷¾× µµÆ÷ Ç¥º»À» 80% ¸ÞŸ³î·Î °íÁ¤ÇÏ¿©,
  • acoustic reflex test
    û°¢¹Ý»ç ½ÃÇè
    û°¢¹Ý»ç ¿ªÄ¡ÀÇ ÃøÁ¤¹ýÀ¸·Î¼­ Àüµµ¼º°ú °¨°¢½Å°æ¼º ³­Ã»À» °¨º° Áø´ÜÇϰųª û½Å°æÁ¾À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÈ´Ù.
  • ACTH stimulation test
    ACTH ÀÚ±Ø °Ë»ç
    Çϼöü ºÎ½ÅÇÇÁú°è ¿¹ºñ·Â°Ë»çÀÇ Çϳª. ºÎ½ÅÇÇÁúÀÚ±Ø È£¸£¸ó
  • Addis test
    ¾Æµð½º ½ÃÇè
    12½Ã°£ µ¿¾È ¿äÀÇ ÀÏÁ¤·® Áß ÀûÇ÷±¸ ¼ö, ¹éÇ÷±¸ ¼ö, »óÇǼ¼Æ÷, ¿øÁÖ, ´Ü¹é ÇÔ·®ÀÇ ÃøÁ¤. ½ÅÀå ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ »ç¿ëµÈ´Ù.
  • additional diagnostic test
    ºÎ°¡Àû Áø´Ü¹ý
  • Adler's test
    ¾Æµé·¯ ½ÃÇè
    µ¿ÀǾî=benzidine test. º¥ÁöµòÀÇ ºùÃÊ»ê Æ÷È­ ¿ë¾×¿¡ °°Àº ¾çÀÇ 3% °ú»êÈ­¼ö¼Ò¿Í ÇÇ°Ë¾× 1 §¢¸¦ °¡ÇÏ¿© û»öÀÌ »ý±â¸é Ç÷¾×ÀÌ Á¸ÀçÇÏ´Â °ÍÀÌ´Ù.
  • adsorption test
    ÈíÂø ½ÃÇè
  • agglutination test
    ÀÀÁý ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pemphigus erythematosus An eruption involving sun-exposed skin, especially the face; the lesions are scaling erythematous macules and blebs, combining the clinical features of both lupus erythematosus and pemphigus vulgaris; bullae are subcorneal; probably a variant of pemphigus foliaceus.
Synonym: Senear-Usher disease, Senear-Usher syndrome.
(05 Mar 2000)
chilblain lupus Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains.
Synonym: chilblain lupus.
(05 Mar 2000)
neonatal lupus Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life.
(05 Mar 2000)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
lupus A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis.
(27 Sep 1997)
lupus anticoagulant An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus.
(27 Sep 1997)
lupus anticoagulants Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT).
Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area.
See also cardiolipin antibodies and phospholipid antibodies.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
lupus erythematodes Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus glomerulonephritis-pathology Patient survival and preservation of renal function are predictable from renal pathology as demonstrated by biopsy and defined by the histological classification of the International Study of Kidney Disease in Children/World Health Organization (ISKDC/WHO). Semi-quantitative indices of nephron loss (chronicity index) and activity of acute potentially reversible inflammation (activity index) are not predictive of individual outcome, renal failure or death in patients with aggressively treated SLE GN.
(05 Mar 2000)
lupus-like syndrome <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause.
(05 Mar 2000)
lupus livido Persistent cyanotic lesions on the extremities, associated with the cutaneous manifestations of Raynaud's disease.
(05 Mar 2000)
lupus lymphaticus A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lupus miliaris disseminatus faciei A millet-like papular eruption of the face, associated with a (histopathologically) tuberculoid perifollicular infiltration, but probably related to rosacea rather than tuberculous infection.
(05 Mar 2000)
lupus mutilans Cutaneous tuberculosis with extensive destruction of tissue.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
  • fatigue test
    ÇÇ·Î ½ÃÇè
  • film test
    ¿µÈ­ ¹è¿ì Áö¸ÁÀÚÀÇ Ä«¸Þ¶ó Å×½ºÆ®
  • herd test
    ¼Ò¶¼ÀÇ °Ë»ç(ƯÁ¤ Á¥¼Ò¶¼ÀÇ À¯Áö¹æ ÇÔÀ¯À² °Ë»ç)
  • inkblot test
    RORSCHACH TEST
  • intelligence test
    ±â´É°Ë»ç
  • intradermal test
    (ÀÇ)Çdz»(¸é¿ª)Å×½ºÆ®
  • mantoux test
    ¸ÁÅõ ¹ÝÀÀ (°áÇÙÀ̳ª °¨¿°ÀÇ °Ë»ç¿ë)
  • means test
    (¿µ) ¼öÀÔ (ÀÚ»ê) Á¶»ç(»ýȰ º¸È£µîÀ» ¹Þ´Â ÀÚÀÇ)
  • mental test
    Áö´É °Ë»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á